ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
May 15, 2026 6:00 AM EDTQ1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million
CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June
Sales force expansion to 148 representatives completed
Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout
Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET
SAN DIEGO, May 15, 2026 (GLOBE... More
